A method for synthesizing trametinib key intermediate

A technology for trametinib and intermediates, which is applied in the field of synthesizing key intermediates of trametinib, can solve the problems of many steps, low yield of one step, low yield of key steps, etc., and achieves the effect of short steps

Active Publication Date: 2021-02-05
安庆奇创药业有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are still many steps in this method, and the one-step yield of compound 5 obtained by condensation is relatively low.
[0005] Wherein compound 5 is a key intermediate for the synthesis of trametinib, yet there are many steps in the two methods reported in the literature, and the problem that the key step yield is too low, therefore, the improvement of compound 5 synthetic method is of great benefit to trametinib The preparation of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for synthesizing trametinib key intermediate
  • A method for synthesizing trametinib key intermediate
  • A method for synthesizing trametinib key intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] according to image 3 The shown roadmap prepares the key intermediate of synthetic trametinib:

[0034] S1: At room temperature, oxalyl chloride (13.4mL, 153mmol) was slowly added dropwise to a suspension of methylmalonic acid (9.0g, 76.2mmol) and DMF (2 drops) in dichloromethane (500mL), and reacted at room temperature for 24h , the solution was homogeneous, and slowly added dropwise to a solution of monoethyl malonate (9.2g, 63.4mmol) in dry toluene (100mL). NaOH solution (1mol / L, 100mL), separate the layers, take the solution layer, continue to add NaOH solution (1mol / L, 100mL) to the organic layer, combine the solution layers, wash with dichloromethane (200mL), adjust the pH to 1 with concentrated hydrochloric acid , ethyl acetate (50mL once, 3 times in total) extracted the aqueous layer, combined the ethyl acetate phases, dried, filtered, and concentrated to obtain a crude product, which was directly put into the next step without purification;

[0035] S2: To a ...

Embodiment 2

[0037]S1: At room temperature, slowly add oxalyl chloride (13.4mL, 153mmol) dropwise to a suspension of methylmalonic acid (9.0g, 76.2mmol) and DMF (2 drops) in dichloromethane (450mL), and react at room temperature for 20h , the solution was homogeneous, and was slowly added dropwise to a solution of monoethyl malonate (8.13g, 56mmol) in dry toluene (82mL). solution (0.8mol / L, 82mL), separate the layers, take the solution layer, continue to add NaOH solution (0.8mol / L, 82mL) to the organic layer, combine the solution layers, wash with dichloromethane (164mL), and adjust the pH to 1. Extract the aqueous layer with ethyl acetate (50 mL once, 3 times in total), combine the ethyl acetate phases, dry, filter, and concentrate to obtain a crude product, which is directly put into the next step without purification;

[0038] S2: To a solution of N-(2-fluoro-4-iodophenyl)-N'-cyclopropylurea (17.9g, 56mmol) in THF (280mL), add sodium ethylate (11.4 g, 168mmol), warmed to room temperat...

Embodiment 3

[0040] S1: Slowly add oxalyl chloride (13.4mL, 153mmol) dropwise to a suspension of methylmalonic acid (9.0g, 76.2mmol) and DMF (2 drops) in dichloromethane (540mL) at room temperature, and react at room temperature for 36h , the solution was homogeneous, slowly added dropwise to a solution of monoethyl malonate (11.05g, 76.2mmol) in dry toluene (132mL), after the addition was completed, the reaction was continued at 50°C for 20h, NaOH solution (1.2mol / L, 132mL), separate the layers, take the solution layer, continue to add NaOH solution (0.8mol / L, 82mL) to the organic layer, combine the solution layers, wash with dichloromethane (264mL), adjust the pH with concentrated hydrochloric acid To 1, extract the aqueous layer with ethyl acetate (50 mL once, 3 times in total), combine the ethyl acetate phases, dry, filter, and concentrate to obtain a crude product, which is directly put into the next step without purification;

[0041] S2: To a solution of N-(2-fluoro-4-iodophenyl)-N'...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a method for synthesizing a key intermediate of trametinib, which uses monoformamide monoethyl malonate and methylmalonic acid to complete the cyclization reaction to obtain a crude pyridinetrione compound; the obtained pyridinetrione The crude compound is directly cyclized with N-(2-fluoro-4-iodophenyl)-N'-cyclopropylurea to obtain the key intermediate of trametinib. The present invention adopts monoethyl malonate and methylmalonic acid to complete the cyclization reaction to obtain a pyridinetrione compound, which is directly cyclized with a urea compound without purification to obtain a key intermediate for synthesizing trametinib. The method steps are short, the total yield is 47.3%, and it has the potential of scale-up in pilot scale, which provides a new scheme for the synthesis of trametinib.

Description

technical field [0001] The invention relates to a synthesis method of trametinib, in particular to a method for synthesizing a key intermediate of trametinib. Background technique [0002] The Chinese chemical name of Trametinib: N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-3,4,6,7-tetra Hydrogen-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1(2H)-yl]phenyl]acetamide, developed by GlaxoSmithKline , Trametinib approved by the U.S. FDA on May 29, 2013, was launched in the U.S. under the trade name Mekinist. For the treatment of unresectable or metastatic melanoma with BRAF (murine sarcoma virulence oncogenic homologue B1 gene) V600E or V600K mutation. [0003] ACS Medicinal Chemistry Letters, 2011,2(4),320-324 reported its synthetic method, as figure 1 Shown: Urea 1 was prepared by using 2-fluoro-4-iodophenylisocyanate and cyclopropylamine, and then cyclized with malonic acid to obtain pyrimidinetrione compound 2, pyrimidinetrione compound 2 and POCl 3 Selective ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D471/04
CPCC07D471/04
Inventor 吴学平储贻结
Owner 安庆奇创药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap